Reproducing abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome by inhibiting the conversion of 7-dehydrocholesterol to cholesterol in rats.
Open Access
- 1 January 1995
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 95 (1) , 76-81
- https://doi.org/10.1172/jci117678
Abstract
The Smith-Lemli-Opitz syndrome is a recessive inherited disorder characterized by neurologic developmental defects and dysmorphic features in many organs. Recently, abnormal cholesterol biosynthesis with impaired conversion of 7-dehydrocholesterol to cholesterol has been discovered in homozygotes. To reproduce the biochemical abnormality, BM 15.766, a competitive inhibitor of 7-dehydrocholesterol-delta 7-reductase, the enzyme that catalyzes the conversion of 7-dehydrocholesterol into cholesterol was fed by gavage to rats. After 14 d, plasma cholesterol concentrations declined from 48 mg/dl to 16 mg/dl and 7-dehydro-cholesterol levels rose from trace to 17 mg/dl. Hepatocytes surrounding the central vein developed balloon necrosis. Stimulating cholesterol synthesis with cholestyramine followed by BM 15.766 produced an additional 40% decline (P < 0.05) in plasma cholesterol and 34% increase in 7-dehydrocholesterol levels compared to the inhibitor alone. Adding 2% cholesterol to the diet during the second week of BM 15.766 treatment increased plasma cholesterol threefold and decreased 7-dehydrocholesterol concentrations 55%. Hepatic 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase activity increased 73% with a 3.9-fold rise in mRNA levels but cholesterol 7 alpha-hydroxylase activity decreased slightly though mRNA levels increased 1.4 times with BM 15.766 treatment. These results demonstrate that BM 15.766 is a potent inhibitor of 7-dehydrocholesterol-delta 7-reductase. The model reproduces abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome and is useful to test different treatment strategies. Stimulating early steps of cholesterol synthesis worsens the biochemical abnormalities while feeding cholesterol inhibits abnormal synthesis, improves the biochemical abnormalities and prevents liver damage.Keywords
This publication has 14 references indexed in Scilit:
- Defective Cholesterol Biosynthesis Associated with the Smith-Lemli-Opitz SyndromeNew England Journal of Medicine, 1994
- A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis.Journal of Clinical Investigation, 1990
- Cholesterol-mediated regulation of HMG-CoA reductase in microsomes from human skin fibroblasts and rat liverBiochemistry and Cell Biology, 1990
- The effect of abnormal plasma and cellular sterol content and composition on low density lipoprotein uptake and degradation by monocytes and lymphocytes in sitosterolemia with xanthomatosisMetabolism, 1988
- Smith‐Lemli‐Opitz (RSH) syndrome bibliographyAmerican Journal of Medical Genetics, 1987
- The effects of BM 15.766, an inhibitor of 7-dehydrocholesterol δ7-reductase∗, on cholesterol biosynthesis in primary rat hepatocytesBiochemical Pharmacology, 1986
- Possible abnormalities of steroid secretion in children with Smith-Lemli-Opitz syndrome and their parentsSteroids, 1985
- Effects of BM 15.766 on Serum Lipids in RatsHormone and Metabolic Research, 1985
- Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-CelluloseProceedings of the National Academy of Sciences, 1972
- A newly recognized syndromeof multiple congenital anomaliesThe Journal of Pediatrics, 1964